Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYX OTCMKTS:AFFY OTCMKTS:ATRX OTCMKTS:PXXLF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A2.16N/AN/AAFFYAffymax$0.00$0.00$0.00▼$0.00N/A7.592,004 shsN/AATRXAdhera Therapeutics$0.00$0.00▼$0.02N/A4628 shs2 shsPXXLFPOXEL FRANCE$0.25$0.25$0.25▼$0.25N/A-0.38N/AN/A10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%0.00%+14.29%0.00%+14.29%ATRXAdhera Therapeutics0.00%0.00%0.00%0.00%-98.75%PXXLFPOXEL FRANCE0.00%0.00%0.00%0.00%-64.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APXXLFPOXEL FRANCEN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/AAFFYAffymax 0.00N/AN/AN/AATRXAdhera Therapeutics 0.00N/AN/AN/APXXLFPOXEL FRANCE 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/AN/APXXLFPOXEL FRANCE$710KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AATRXAdhera Therapeutics-$2.11MN/A0.00N/AN/AN/AN/AN/AN/APXXLFPOXEL FRANCE-$33.08MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AATRXAdhera TherapeuticsN/AN/AN/AN/AN/APXXLFPOXEL FRANCEN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/AAFFYAffymaxN/AATRXAdhera TherapeuticsN/APXXLFPOXEL FRANCEN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%AFFYAffymax1.55%ATRXAdhera Therapeutics28.20%PXXLFPOXEL FRANCEN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6N/AN/ANot OptionableAFFYAffymax4N/AN/ANot OptionableATRXAdhera Therapeutics211.63 million8.35 millionNot OptionablePXXLFPOXEL FRANCE15N/AN/ANot OptionablePXXLF, ATRX, AFFY, and ADYX HeadlinesRecent News About These CompaniesPoxel Announces the Opening of Reorganization ProceedingsAugust 8 at 12:18 PM | uk.finance.yahoo.comFollowing the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate GovernanceAugust 1, 2025 | businesswire.comPoxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of TradingJuly 29, 2025 | businesswire.comPoxel S.A. (PXXLF) Stock Price, Quote, News & Analysis - Seeking AlphaJuly 2, 2025 | seekingalpha.comPoxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update - Yahoo FinanceJuly 2, 2025 | uk.finance.yahoo.comPoxel annonce le report de son Assemblée Générale annuelle et fait le point sur sa situationJune 30, 2025 | fr.finance.yahoo.comPoxel Announces Postponement of its Annual General Meeting and Provides a Corporate UpdateJune 30, 2025 | businesswire.comPoxel : cinq présentations lors des 85ème sessions scientifiques de l'ADAJune 20, 2025 | bourse.lefigaro.frBPoxel : va présenter des données sur l'ImeglimineJune 19, 2025 | zonebourse.comZPoxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes ConferenceJune 19, 2025 | businesswire.comForgotten Fragments - Official Demo TrailerJune 13, 2025 | msn.comTen Years of the Loewe Puzzle Bag: A Cubist Classic Celebrates a DecadeMay 29, 2025 | vogue.comVGoogle Pixel 10 Pro: Ultimate Preview GuideMay 29, 2025 | msn.comJuufuutei Raden’s Guide for Pixel Museum launches June 5May 28, 2025 | gematsu.comGGoogle Pixel 10: Ultimate Preview GuideMay 28, 2025 | msn.com"Valve never made a Portal 2 sequel. So we did," claims impossibly bold indie puzzler which actually reminds me more of a different puzzle gameMay 27, 2025 | msn.comPoxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025May 26, 2025 | businesswire.comTormenture Update Makes It Smoother Than Ever, Available at 25% Discount on SteamMay 22, 2025 | cogconnected.comCPoxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate UpdateMay 13, 2025 | businesswire.comALRUNA and the NECRO-INDUSTRIALISTS Out now on Nintendo SwitchMay 7, 2025 | dlh.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimePXXLF, ATRX, AFFY, and ADYX Company DescriptionsAlliqua BioMedical OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Affymax OTCMKTS:AFFY$0.0008 0.00 (0.00%) As of 08/8/2025Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Adhera Therapeutics OTCMKTS:ATRXAdhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.POXEL FRANCE OTCMKTS:PXXLF$0.25 0.00 (0.00%) As of 08/8/2025Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
